Literature DB >> 19742145

Cetuximab for patients with colon cancer and hepatic metastasis complicated by liver dysfunction and icterus.

Kohei Shitara1, Tomoya Yokota, Setsuo Utsunomiya.   

Abstract

Entities:  

Year:  2009        PMID： 19742145      PMCID： PMC2739644     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  12 in total

1.  Trastuzumab plus estrogen suppression as salvage treatment in a case of liver failure due to metastatic breast cancer.

Authors:  Andrea A Martoni; Alessandra Bernardi; Sara Quercia
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

2.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

Authors:  W De Roock; H Piessevaux; J De Schutter; M Janssens; G De Hertogh; N Personeni; B Biesmans; J-L Van Laethem; M Peeters; Y Humblet; E Van Cutsem; S Tejpar
Journal:  Ann Oncol       Date:  2007-11-12       Impact factor: 32.976

3.  Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia.

Authors:  Nicolas Moosmann; Dorit Laessig; Henrik Jakob Michaely; Christoph Schulz; Volker Heinemann
Journal:  Onkologie       Date:  2007-09-21

4.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

5.  Cetuximab for the treatment of colorectal cancer.

Authors:  Derek J Jonker; Chris J O'Callaghan; Christos S Karapetis; John R Zalcberg; Dongsheng Tu; Heather-Jane Au; Scott R Berry; Marianne Krahn; Timothy Price; R John Simes; Niall C Tebbutt; Guy van Hazel; Rafal Wierzbicki; Christiane Langer; Malcolm J Moore
Journal:  N Engl J Med       Date:  2007-11-15       Impact factor: 91.245

6.  A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

Authors:  A P Venook; C Enders Klein; G Fleming; D Hollis; C G Leichman; R Hohl; J Byrd; D Budman; M Villalona; J Marshall; G L Rosner; J Ramirez; H Kastrissios; M J Ratain
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

Review 7.  Part II: Liver function in oncology: towards safer chemotherapy use.

Authors:  Kathryn M Field; Michael Michael
Journal:  Lancet Oncol       Date:  2008-12       Impact factor: 41.316

8.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

9.  Therapeutic options in patients with lymphoma and severe liver dysfunction.

Authors:  Irene M Ghobrial; Robert C Wolf; Denise L Pereira; Rafael Fonseca; William L White; Joseph P Colgan; Thomas M Habermann; David J Inwards; Svetomir N Markovic; Stephen M Ansell; Ivana N M Micallef; Luis F Porrata; Thomas E Witzig
Journal:  Mayo Clin Proc       Date:  2004-02       Impact factor: 7.616

10.  Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.

Authors:  Daniel J Sargent; Claus Henning Köhne; Hanna Kelly Sanoff; Brian M Bot; Matthew T Seymour; Aimery de Gramont; Ranier Porschen; Leonard B Saltz; Philippe Rougier; Christopher Tournigand; Jean-Yves Douillard; Richard J Stephens; Axel Grothey; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
View more
  2 in total

1.  Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature.

Authors:  Julia Quidde; Marc Azémar; Carsten Bokemeyer; Dirk Arnold; Alexander Stein
Journal:  Ther Adv Med Oncol       Date:  2016-03-17       Impact factor: 8.168

2.  Targeting intracranial patient-derived glioblastoma (GBM) with a NIR-I fluorescent immunoconjugate for facilitating its image-guided resection.

Authors:  Kenneth S Hettie; Nutte Tarn Teraphongphom; Robert D Ertsey; Eben L Rosenthal; Frederick T Chin
Journal:  RSC Adv       Date:  2020-11-23       Impact factor: 4.036
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.